Nasdaq - Delayed Quote
USD
Fidelity Select Biotechnology (FBIOX)
29.01
+0.42
(+1.47%)
As of 8:10:12 AM EDT. Market Open.
Performance Overview
| Morningstar Return Rating | -- |
| YTD Return | 16.28% |
|---|---|
| 5y Average Return | 7.95% |
| Number of Years Up | 30 |
| Number of Years Down | 10 |
| Best 1Y Total Return (Oct 26, 2026) | 65.66% |
| Worst 1Y Total Return (Oct 26, 2026) | -- |
| Best 3Y Total Return | 65.66% |
| Worst 3Y Total Return | -6.72% |
Trailing Returns (%) Vs. Benchmarks
Monthly Total Returns
FBIOX
Category
- YTD
- 19.64%
- 7.95%
- 1-Month
- -5.07%
- 4.81%
- 3-Month
- -0.76%
- 7.18%
- 1-Year
- 37.90%
- 30.16%
- 3-Year
- 26.22%
- 16.10%
- 5-Year
- 8.28%
- 15.71%
- 10-Year
- 10.71%
- 15.27%
- Last Bull Market
- 44.99%
- 23.06%
- Last Bear Market
- -10.44%
- -13.88%
Annual Total Return (%) History
Year
FBIOX
Category
Past Quarterly Returns
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
|
2026
|
2.11% | 18.07% | -0.76% | -- |
|
2025
|
-1.38% | -2.48% | 23.03% | 15.26% |
|
2024
|
10.54% | -1.34% | 9.55% | -10.21% |
|
2023
|
-3.99% | 6.21% | -6.02% | 14.88% |
|
2022
|
-16.38% | -10.44% | 6.90% | 5.10% |
|
2021
|
-4.37% | 1.37% | -1.55% | -8.19% |
|
2020
|
-14.71% | 33.64% | 0.84% | 20.36% |
|
2019
|
20.01% | -1.20% | -9.41% | 26.57% |
|
2018
|
3.07% | 5.41% | 5.76% | -22.31% |
|
2017
|
15.79% | 4.75% | 10.26% | -4.39% |
Rank in Category (By Total Return)
| YTD | 25 |
| 1-Month | 86 |
|---|---|
| 3-Month | 76 |
| 1-Year | 28 |
| 3-Year | 10 |
| 5-Year | 15 |
Load Adjusted Returns
| 1-Year | 37.90% |
| 3-Year | 26.22% |
|---|---|
| 5-Year | 8.28% |
| 10-Year | 10.71% |
Performance & Risk
| YTD Return | 16.28% |
| 5y Average Return | 7.95% |
| Rank in Category (ytd) | 25 |
| % Rank in Category (ytd) | -- |
| Beta (5Y Monthly) | 0.71 |
| Morningstar Risk Rating |
Fund Overview
| Category | Health |
| Fund Family | Fidelity Investments |
| Net Assets | 5.98B |
| YTD Return | 19.64% |
| Yield | 1.47% |
| Morningstar Rating | |
| Inception Date | Dec 16, 1985 |
Fund Summary
The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.
